The picture does get clearer...money makes the world go around! Well I know that Donald Rumsfeld has a huge stake in Gilead....would anyone trust that oily war monger? Though I'm not a communist I wish that medical drug research was done by the state for the people without profit even entering the equation. Sovaldi was developed by Pharmasset using public funds in America, all Gilead did was steal the glory & triple the price! I don't have a clue what is coming down the pike for type three's like me? But I bet it's equally prohibitively expensive?
Loopy Lisa said
Oct 13, 2014
Its OK having all these combos, but they are nothing if we can't access them. I wonder what I pay insurance for now!
Huey said
Oct 13, 2014
I think they will stop making Sovaldi by itself, because Sovaldi is better with Ledi than Sovaldi alone. This will make the 2'S and 3's cost more, and still for 24 weeks and still with riba/
This makes Gilead more money but raise's the bar on the RAV's That is totally unfair.
-- Edited by Huey on Monday 13th of October 2014 06:40:56 AM
Isiscat2011 said
Oct 12, 2014
Tig56 wrote:
Perhaps it's as simple as wanting the whole pie all to themselves? I'm sure Riba would offer a more affordable price structure, but Gilead doesn't care to share in the glory... This picture keeps getting clearer and clearer!
Wow, that is really greedy. If they pulled Sovaldi (sold alone) from the market there would also be zero chance of Daclatasvir or any other DAA being used with it (even off label).
Tig said
Oct 12, 2014
Perhaps it's as simple as wanting the whole pie all to themselves? I'm sure Riba would offer a more affordable price structure, but Gilead doesn't care to share in the glory... This picture keeps getting clearer and clearer!
Tig
mallani said
Oct 12, 2014
Hi all,
I must admit that I'm confused about the message Gilead is sending to the Genotype 3's. In the Prescribing Information for Harvoni, it states that Ledipasvir has reduced activity against Genotypes 2 and 3.
However, the ongoing Electron2 Trial (Harvoni +/- Riba for 12 weeks), gives 100% SVR rates for geno 3 if Riba is used.
Perhaps they are holding out for their new pan-genotype NS-5A inhibitor- GS-5816.
The picture does get clearer...money makes the world go around! Well I know that Donald Rumsfeld has a huge stake in Gilead....would anyone trust that oily war monger? Though I'm not a communist I wish that medical drug research was done by the state for the people without profit even entering the equation. Sovaldi was developed by Pharmasset using public funds in America, all Gilead did was steal the glory & triple the price! I don't have a clue what is coming down the pike for type three's like me? But I bet it's equally prohibitively expensive?
Its OK having all these combos, but they are nothing if we can't access them. I wonder what I pay insurance for now!
I think they will stop making Sovaldi by itself, because Sovaldi is better with Ledi than Sovaldi alone. This will make the 2'S and 3's cost more, and still for 24 weeks and still with riba/
This makes Gilead more money but raise's the bar on the RAV's That is totally unfair.
-- Edited by Huey on Monday 13th of October 2014 06:40:56 AM
Wow, that is really greedy. If they pulled Sovaldi (sold alone) from the market there would also be zero chance of Daclatasvir or any other DAA being used with it (even off label).
Perhaps it's as simple as wanting the whole pie all to themselves? I'm sure Riba would offer a more affordable price structure, but Gilead doesn't care to share in the glory... This picture keeps getting clearer and clearer!
Tig
Hi all,
I must admit that I'm confused about the message Gilead is sending to the Genotype 3's. In the Prescribing Information for Harvoni, it states that Ledipasvir has reduced activity against Genotypes 2 and 3.
However, the ongoing Electron2 Trial (Harvoni +/- Riba for 12 weeks), gives 100% SVR rates for geno 3 if Riba is used.
Perhaps they are holding out for their new pan-genotype NS-5A inhibitor- GS-5816.
http://www.aidsmap.com/Sofosbuvir-new-GS-5816-NS5A-inhibitor-is-effective-against-hepatitis-C-genotypes-1-6/page/2847422/